Zika virus and brain cancer: Can Zika be an effective treatment for brain cancer? A systematic review.

Q2 Medicine Oncotarget Pub Date : 2024-09-30 DOI:10.18632/oncotarget.28647
Mateus Gonçalves de Sena Barbosa, Beatriz Rodrigues Messias, Rafael Trindade Tatit, Maycon Cristian Gomes de Paula, Valdecir Boeno Spenazato Júnior, Maria Gabriella Borges Braga, Caio Vinícius Marcolino Santos, Luiza D'Ottaviano Cobos, Vinícius Otávio da Silva, Eberval Gadelha Figueiredo, Nicollas Nunes Rabelo, Bipin Chaurasia
{"title":"Zika virus and brain cancer: Can Zika be an effective treatment for brain cancer? A systematic review.","authors":"Mateus Gonçalves de Sena Barbosa, Beatriz Rodrigues Messias, Rafael Trindade Tatit, Maycon Cristian Gomes de Paula, Valdecir Boeno Spenazato Júnior, Maria Gabriella Borges Braga, Caio Vinícius Marcolino Santos, Luiza D'Ottaviano Cobos, Vinícius Otávio da Silva, Eberval Gadelha Figueiredo, Nicollas Nunes Rabelo, Bipin Chaurasia","doi":"10.18632/oncotarget.28647","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Many studies have highlighted the use of oncolytic viruses as a new class of therapeutic agents for central nervous system (CNS) tumors, especially glioblastomas (GMB). Zika Virus (ZIKV) proteins targeted to specific stem cells have been studied <i>in vitro</i> and animal models with promising results.</p><p><strong>Materials and methods: </strong>A systematic review was evaluated the efficacy and safety of the ZIKV use for CNS tumors treatment. Data were extracted and the <i>in vivo</i> studies were evaluated using the Robins-I tool. We assessed bias in each study using criteria such as selection bias, performance bias, detection bias, attrition bias, reporting bias, and others. According to Cochrane guidelines, bias was classified as high, low, or uncertain. High bias occurred when studies did not meet the criteria. Low bias was assigned when criteria were clearly met. Uncertain bias reflected insufficient information for a clear classification.</p><p><strong>Results: </strong>The 14 included studies shown that ZIKV reduced cell viability or inhibited the growth, proliferation of glioma stem cells (GSCs), and Bcl2 expression - which could potentially enhance the effect of chemotherapy/radiotherapy; caused cytopathic effects, induced tumor cell damage, manifested oncolytic properties, and even selectively safely killed GSCs; ultimately, it led to significant tumor remission and enhanced long-term survival through enhanced T-cell response.</p><p><strong>Conclusions: </strong>Although current evidence suggests ZIKV as a promising treatment for CNS tumors and may improve survival when combined with surgery and radiotherapy. Despite limited human evidence, it shows potential benefits. Further research is needed to confirm safety, efficacy, and optimize treatment in humans.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"662-673"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11441410/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncotarget","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/oncotarget.28647","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Many studies have highlighted the use of oncolytic viruses as a new class of therapeutic agents for central nervous system (CNS) tumors, especially glioblastomas (GMB). Zika Virus (ZIKV) proteins targeted to specific stem cells have been studied in vitro and animal models with promising results.

Materials and methods: A systematic review was evaluated the efficacy and safety of the ZIKV use for CNS tumors treatment. Data were extracted and the in vivo studies were evaluated using the Robins-I tool. We assessed bias in each study using criteria such as selection bias, performance bias, detection bias, attrition bias, reporting bias, and others. According to Cochrane guidelines, bias was classified as high, low, or uncertain. High bias occurred when studies did not meet the criteria. Low bias was assigned when criteria were clearly met. Uncertain bias reflected insufficient information for a clear classification.

Results: The 14 included studies shown that ZIKV reduced cell viability or inhibited the growth, proliferation of glioma stem cells (GSCs), and Bcl2 expression - which could potentially enhance the effect of chemotherapy/radiotherapy; caused cytopathic effects, induced tumor cell damage, manifested oncolytic properties, and even selectively safely killed GSCs; ultimately, it led to significant tumor remission and enhanced long-term survival through enhanced T-cell response.

Conclusions: Although current evidence suggests ZIKV as a promising treatment for CNS tumors and may improve survival when combined with surgery and radiotherapy. Despite limited human evidence, it shows potential benefits. Further research is needed to confirm safety, efficacy, and optimize treatment in humans.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
寨卡病毒与脑癌寨卡病毒能有效治疗脑癌吗?系统综述。
导言:许多研究都强调将溶瘤病毒作为治疗中枢神经系统(CNS)肿瘤,尤其是胶质母细胞瘤(GMB)的新型药物。针对特定干细胞的寨卡病毒(ZIKV)蛋白已在体外和动物模型中进行了研究,并取得了可喜的成果:对使用 ZIKV 治疗中枢神经系统肿瘤的有效性和安全性进行了系统性评估。采用罗宾斯-I工具提取数据并评估体内研究。我们使用选择偏倚、表现偏倚、检测偏倚、自然减员偏倚、报告偏倚等标准评估了每项研究的偏倚。根据 Cochrane 指南,偏倚分为高、低和不确定。当研究不符合标准时,就会出现高偏倚。当研究明显符合标准时,偏倚程度为低。不确定偏倚反映了信息不足,无法进行明确分类:纳入的14项研究表明,ZIKV可降低细胞活力或抑制胶质瘤干细胞(GSCs)的生长、增殖和Bcl2的表达--这有可能增强化疗/放疗的效果;ZIKV可引起细胞病理效应、诱导肿瘤细胞损伤、表现出溶瘤特性,甚至可选择性地安全杀死GSCs;最终,ZIKV可通过增强T细胞反应使肿瘤显著缓解并提高长期生存率:结论:尽管目前的证据表明,ZIKV 是一种治疗中枢神经系统肿瘤的有前途的药物,与手术和放疗相结合可提高生存率。尽管人类证据有限,但它仍显示出潜在的益处。还需要进一步的研究来确认其安全性和有效性,并优化人体治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncotarget
Oncotarget Oncogenes-CELL BIOLOGY
CiteScore
6.60
自引率
0.00%
发文量
129
审稿时长
1.5 months
期刊介绍: Information not localized
期刊最新文献
Advancements in cell-penetrating monoclonal antibody treatment. B7-H4: A potential therapeutic target in adenoid cystic carcinoma. Computed tomography-based radiomics and body composition model for predicting hepatic decompensation. Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists. Retraction: Hyperglycemia via activation of thromboxane A2 receptor impairs the integrity and function of blood-brain barrier in microvascular endothelial cells.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1